• Medafor misstatement #2: While CryoLife widely touts its sales force having what it reports to be $6 million in worldwide Hemostase sales, CryoLife fails to mention that Medafor transferred a significant portion of that business in already established sales. (Second sentence of Paragraph 4, Page 2 of Medafor Letter to Shareholders dated February 10, 2010)
• FACT: A significant portion of CryoLife’s sales were generated from its own efforts, not from a transfer by Medafor of established sales. In fact, while the litigation between CryoLife and Medafor is unrelated to this process, part of CryoLife’s contention in the lawsuit against Medafor is that the company did not transfer sales that they were required to, that were CryoLife’s exclusive right.
Comment: Again CRY does not address the substance of the question. As I undersatnd it, Medafor did transfer substantial sales targets to CRY. The fact that CRY was ineffective on selling to these known sales targets perhaps shows that the CRY sale force focuses on selling tissue and BioGlue, and was not very good on the up take. Again, a relatively minor matter made to look like a big deal. More SGA smoke. mirrors, and deception. As one east side to another, that is what I would call it anyway. Did SGA learn any values when he lived on the east side?
Not a real objective analysis. Trying to hard. Cry is going double digits. The more north that cry shares go, the more missed opportunity it is for the Med. s/hs. They should make to deal now and get on the train before it leaves the station. The combined co. will do well for all s/hs. If the deal had been accepted both companies would have already been better off than they are now. More can be gained by cooperation. The end users like a seemless package. Just thought I would put something in here so you did not have to feel like you were talking to yourself. The low response to your posts is a message in itself.